.png){kind=icon}
返回
Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing
.png){kind=icon}
OA
AI
DOI：10.1093/jnci/djy001.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Background: Li-Fraumeni syndrome (LFS) has traditionally been identified by single-gene testing (SGT) of TP53 triggered by clinical criteria, but the widespread use of multigene panel tests (MGPTs) has upended this paradigm. We sought to compare the personal and family cancer histories of TP53-positive result (TP53+) carriers who were identified by either MGPT or SGT. Methods: Of 44310 individuals who underwent testing of TP53 in a single clinical diagnostic laboratory between 2010 and 2014, 44 086 (40885 MGPT and 3201 SGT) met study eligibility criteria. Personal cancer histories were available for 38 938 subjects. The frequency of germline TP53 results and various phenotypic manifestations were compared according to test type. All statistical tests were two-sided. Results: MGPT TP53+ individuals (n = 126) had an older median age at first cancer than SGT TP53+ carriers (n = 96; women: median = 36 vs 28 years, P < .001; and men: median = 40 vs 15 years, P = .004). The median age of breast cancer diagnosis was 40 years in MGPT TP53+ women vs 33 years in SGT TP53+ women (P < .001). In both cohorts, childhood and LFS core cancers, and for women, multiple primary cancers (not multiple breast tumors), were associated with TP53+ results. Established LFS testing criteria were less often met by MGPT TP53+ individuals. Conclusions: MGPT TP53+ individuals differ in phenotype from those ascertained through SGT and are notably older at cancer diagnosis and less likely to meet LFS clinical criteria. These findings suggest that LFS may have a greater phenotypic spectrum than previously appreciated. This has implications for the counseling of MGPT TP53+ individuals. Prospective follow-up of these individuals and families is needed to re-evaluate cancer risks.
Keyword:
LI-FRAUMENI-SYNDROME
P53 GERMLINE MUTATIONS
CANCER-RISK-ASSESSMENT
ONSET BREAST-CANCER
IMAGING SURVEILLANCE
CLONAL HEMATOPOIESIS
HEREDITARY BREAST
FAMILIAL SYNDROME
MULTIGENE PANELS
OVARIAN-CANCER
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
7.2
论文数:
6.2K
被引数:
3.3W
机构
引用论文
Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.png)
GENETICS IN MEDICINEOAAI
GENETICS IN MEDICINEIF6.2
OAAI分享收藏The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysisNUCLEIC ACIDS RESEARCHOAAI
NUCLEIC ACIDS RESEARCHIF13.1
OAAI分享收藏分享收藏Age-related mutations associated with clonal hematopoietic expansion and malignancies与克隆性造血扩增和恶性肿瘤相关的年龄相关突变NATURE MEDICINEOAAI
NATURE MEDICINEIF50
OAAI分享收藏The action of oxytocin originating in the hypothalamic paraventricular nucleus on mitral and granule cells in the rat main olfactory bulbNeuroscience
NeuroscienceIF0
PREAI
分享收藏分享收藏
查看更多内容